EGFr Binding Agent Selection via Mutant Epitope Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current monoclonal antibodies targeting the epidermal growth factor receptor (EGFr) for cancer therapy face challenges in specificity and efficacy, particularly in binding to panitumumab epitopes, which limits their ability to inhibit tumor cell proliferation effectively.
Innovation Solution
A method for selecting specific binding agents that either bind to or avoid binding to panitumumab epitopes on EGFr polypeptides, involving affinity determination for both wild-type and mutant EGFr polypeptides with specific point mutations, to enhance therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used to target EGFr for cancer therapy, then tumor cell proliferation can be inhibited, but specificity and efficacy are limited due to binding to panitumumab epitopes
Solution Approach 1:
The patent applies parameter changes by systematically varying amino acid residues at positions 349, 355, 412, 438, 443, 465, and 467 in the EGFr L2 domain to create mutant variants. This allows identification of mutations that reduce antibody binding affinity while maintaining receptor function, thereby improving therapeutic efficacy by overcoming limitations of current monoclonal antibodies that bind to panitumumab epitopes
Solution Approach 2:
The patent employs preliminary action by pre-selecting specific amino acid positions in the EGFr L2 domain that are critical for antibody binding based on structural analysis and prior knowledge. Mutations are introduced at these predetermined positions to systematically reduce binding affinity to panitumumab and related antibodies before conducting functional assays, streamlining the development of improved binding agents
2Reliability
If binding affinity to EGFr is increased to improve therapeutic efficacy, then tumor cell proliferation inhibition is enhanced, but binding to panitumumab epitopes may increase causing reduced specificity
Solution Approach 1:
The patent applies local quality by making targeted amino acid substitutions at specific positions (349, 355, 412, 438, 443, 465, 467) within the L2 domain rather than globally modifying the entire receptor. This localized modification approach allows reduction of binding affinity to panitumumab epitopes at specific binding interfaces while preserving overall EGFr structure and function, thereby achieving improved specificity without sacrificing inhibition efficacy
Solution Approach 2:
The patent segments the EGFr L2 domain into specific amino acid positions that can be independently mutated. By dividing the binding interface into discrete mutable positions, the patent enables systematic optimization of binding properties - reducing affinity for panitumumab while maintaining or enhancing affinity for therapeutic antibodies, thus resolving the contradiction between binding strength and specificity
Data Source
AI summary
The present application relates to methods of selecting EGFr binding agents. In certain embodiments, such EGFr binding agents bind to at least a portion of a panitumumab epitope on an EGFr. In certain embodiments, such EGFr binding agents do not bind to a panitumumab epitope on an EGFr.